annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 35A The utility of PET/CT in the treatment management of gastroesophageal
cancer (GEC): Impact on staging and treatment decisions. (Abstract #4138)
W. Shan, C. K. Kollmannsberger, D. Wilson, A. Briede, C. D. Blanke, H. J. Lim
Brd. 35B Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy
(G-RT) in patients (pts) with locally advanced unresectable pancreatic
adenocarcinoma (LAUPC). (Abstract #4139)
S. Anderson, H. R. Cardenes, F. Akisik, E. L. Johnston, R. Clark, S. M. Perkins,
C. S. Johnson, P. J. Loehrer, B. P. Schneider, E. G. Chiorean
Brd. 35C Use of serum VEGF (SVEGF) levels to predict outcome of esophageal
cancer (EC) patients undergoing preoperative chemoradiation (CRT).
(Abstract #4140)
F. De Vita
Brd. 35D Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat
early and intermediate hepatocellular carcinoma. (Abstract #4141)
A. Nicolini, A. Sangiovanni, M. Iavarone, L. Martinetti, M. A. Manini, S. Crespi,
C. Della Corte, S. Vavassori, M. Colombo
Brd. 35E Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen
(TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.
(Abstract #4142)
M. Dalla Chiesa, R. Poli, G. Tomasello, S. Lazzarelli, S. Buti, M. Brighenti, F. Negri,
A. Curti, A. Auzzani, R. Passalacqua
Brd. 35F Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in
patients with advanced pancreatic cancer. (Abstract #4143)
S. J. Lubner, W. R. Schelman, D. Mulkerin, K. D. Holen, S. Seo, N. K. LoConte
Brd. 35G Dose-painted intensity-modulated radiation therapy for anal cancer: A
multi-institutional report of acute toxicity and response to therapy.
(Abstract #4144)
T. S. Hong, H. K. Tsai, J. Coen, L. S. Blaszkowsky, K. L. Hartshorn, E. L. Kwak,
J. Willins, D. P. Ryan, L. A. Kachnic
Brd. 35H A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer.
(Abstract #4145)
E. Suzuki, M. Ikeda, T. Okusaka, S. Nakamori, S. Ohkawa, T. Nagakawa, N. Boku,
H. Yamagimoto, K. Sugimori, J. Furuse
Brd. 36A Upregulation of multidrug resistance-associated protein 4 in the early stage
of vascular invasion of hepatocellular carcinoma. (Abstract #4146)
K. Higuchi, T. Terada, M. Fukudo, K. Ogasawara, T. Katsura, E. Hatano, I. Ikai,
K. Inui
Brd. 36B A feasibility analysis from the patient preference randomized phase III
clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer
(AGC) patients pretreated with both fluoropyrimidines and platinum.
(Abstract #4147)
S. Park, S. Lee, J. Kang, I. Hwang, J. Lee, J. Park, Y. Park, H. Lim, W. Kang
Brd. 36C Prediction of prognosis in hepatocellular carcinoma based on a gene
signature from highly tumorigenic liver cancer cells. (Abstract #4148)
X. Yang, J. Fan, Y. Xu, J. Zhou, B. Yu
Brd. 36D Phase I and II studies of intravenous Rexin-G as monotherapy for stage IVb
gemcitabine-resistant pancreatic cancer. (Abstract #4149)
H. Bruckner, S. P. Chawla, C. S. Chua, D. V. Quon, L. Fernandez, A. Saralou,
M. Fisher, E. M. Gordon, F. L. Hall
Brd. 36E Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly
patients (pts) with advanced gastric cancer (AGC). (Abstract #4150)
Y. Becouarn, C. Bellera, R. Brunet, J. Legoux, L. Cany, J. Dauba, D. Smith,
D. Auby, C. Mertens, M. Fonck
275
SUNDAY